WEIZMANN SCIENCE PARK, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company (www.kamada.com) developing, producing and marketing specialty life-saving therapeutics, has successfully concluded Phase I clinical studies designed to test the safety and tolerability of the aerosolized version of its flagship product, Alpha-1 Antitrypsin (AAT) using an optimized eFlow® Electronic Nebulizer (PARI Pharma GmbH) to treat various lung diseases.
